Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.34 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.33 |
| ▸ | ASGR1 | P07306 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | FPR2 | P25090 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 2/20 | 0.31 |
| ▸ | MMP9 | P14780 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1760428 | 1.00 | CA2 (0.41) | CA2HCRTR2TMEM97SIGMAR1ASGR1 | |
| SCHEMBL1760347 | 1.00 | CA2 (0.41) | CA2HCRTR2TMEM97SIGMAR1ASGR1 | |
| SCHEMBL8367145 | 0.84 | CA2 (0.39) | CA2HCRTR2TMEM97SIGMAR1ASGR1 | |
| SCHEMBL1760416 | 0.79 | CA2 (0.44) | CA2HCRTR2TMEM97SIGMAR1ALDH1A1 | |
| SCHEMBL2238201 | 0.74 | SLC6A4 (0.36) | — | |
| SCHEMBL13521525 | 0.73 | HSD11B1 (0.33) | CA2HCRTR2TMEM97SIGMAR1 | |
| SCHEMBL8185362 | 0.73 | HDAC6 (0.35) | CA2HCRTR2TMEM97SIGMAR1ASGR1 | |
| SCHEMBL28924704 | 0.72 | CA2 (0.41) | CA2HCRTR2TMEM97SIGMAR1ALDH1A1 | |
| SCHEMBL28924703 | 0.72 | CA2 (0.41) | CA2HCRTR2TMEM97SIGMAR1ALDH1A1 | |
| SCHEMBL13903965 | 0.72 | CA2 (0.48) | CA2HCRTR2TMEM97SIGMAR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011057993-A1 | INDAZOLONE DERIVATIVES AS GLYCOGEN SYNTHASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-05-19 | — | — | WO | disclosed |
| US-20110112147-A1 | INDAZOLONE ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | BOLIN DAVID ROBERT | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112147-A1 | INDAZOLONE ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | GYS2, GYS1, PYGL | CA2 2462/4885HCRTR2 4762/4885TMEM97 1657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.